RxDoctor Payments Data

Alyssa Smith

Medical · Salt Lake City, UTNPI 1407321680

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,699 and has fallen 54.2% since, to $777 in 2025. Among medical clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,360in general payments, 2019–2025

Across 253 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$1K
  • Amgen$467
  • Lilly USA, LLC$458
  • Boehringer Ingelheim$450
  • Sanofi-aventis U.S. LLC$385
  • Corcept Therapeutics$382
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$5,349100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,360 in reported general payments places this provider in the 90th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$26,982
TrulicityDulaglutide12$21,787
MounjaroTirzepatide11$10,275
TradjentaLinagliptin16$8,900
JardianceEmpagliflozin11$6,794
Levothyroxine Sodium127$1,413
ValacyclovirValacyclovir Hcl27$1,384
Gabapentin77$1,339
Albuterol Sulfate HfaAlbuterol Sulfate67$1,267
Omeprazole82$1,135
Atorvastatin Calcium106$890
Potassium Chloride34$813
Metoprolol Succinate42$767
Rosuvastatin Calcium68$759
Amlodipine Besylate58$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$458$32,06223 claims
PfizerEliquis$52$26,98218 claims
Boehringer IngelheimTradjenta, Jardiance$450$15,69327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 263 medical providers in Utah.

Other medical in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →